References
- 1. N. Ayala-Fontanez, D. C. Soler and T. S. McCormick, Current knowledge on psoriasis and autoimmune diseases, Psoriasis (Auckl)6 (2016) 7–32; https://doi.org/10.2147/PTT.S64950
- 2. C. E. M. Griffiths, J. M. van der Walt, D. M. Ashcroft, C. Flohr, L. Naldi, T. Nijsten and M. Augustin, The global state of psoriasis disease epidemiology: A workshop report, Br. J. Dermatol.177 (2017) e4–e7; https://doi.org/10.1111/bjd.15610
- 3. M. Kaštelan, Psoriasis, Reumatizam64 (2017) 31–36.
- 4. D. A. Springate, R. Parisi, E. Kontopantelis, D. Reeves, C. E. M. Griffiths and D. M. Ashcroft, Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study, Br. J. Dermatol.176 (2017) 650–658; https://doi.org/10.1111/bjd.15021
- 5. P. di Meglio, F. Villanova and F. O. Nestle, Psoriasis, Cold Spring Harb. Perspect. Med.4 (2014) a015354; https://doi.org/10.1101/cshperspect.a015354
- 6. M. A. Lowes, M. Suarez-Farinas and J. G. Krueger, Immunology of psoriasis, Ann. Rev. Immunol.32 (2014) 227–255; https://doi.org/10.1146/annurev-immunol-032713-120225
- 7. J. Takeshita, S. Grewal, S. M. Langan, N. N. Mehta, A. Ogdie, A. S. Van Voorhees and J. M. Gefland, Psoriasis and comorbid diseases. Part I. Epidemiology, J. Am. Acad. Dermatol.76 (2017) 377–390; https://doi.org/10.1016/j.jaad.2016.07.064
- 8. E. Dauden, S. Castaneda, C. Suarez, J. Garcia Campayo, A. J. Blasco, M. D. Aguilar, C. Ferrandiz, L. Puig and J. L. Sanchez-Carazo, Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis, J. Eur. Acad. Dermatol. Venereol.27 (2013) 1387–1404; https://doi.org/10.1111/jdv.12024
- 9. F. O. Nestle, D. H. Kaplan and J. Barker, Psoriasis, N. Eng. J. Med.361 (2009) 496–509; https://doi.org/10.1056/NEJMra0804595
- 10. Global report on psoriasis, World Health Organization 2016. www.who.int
- 11. M. Meštrović, Suvremene spoznaje o etiopatogenezi psorijaze, Sveučilište u Zagrebu, Zagreb 2016.
- 12. M. Haroon, P. Gallagher and O. FitzGerald, Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis, Ann. Rheum. Dis.74 (2015) 1045–1050; https://doi.org/10.1136/annrheumdis-2013-204858
- 13. C. Conrad and M. Gilliet, Psoriasis: from pathogenesis to targeted therapies, Clin. Rev. Allergy Immunol.54 (2018) 102–113; https://doi.org/10.1007/s12016-018-8668-1
- 14. W-H. Boehncke and N. C. Brembilla, Unmet needs in the field of psoriasis: pathogenesis and treatment, Clin. Rev. Allergy Immunol.55 (2018) 295–311; https://doi.org/10.1007/s12016-017-8634-3
- 15. S. R. Feldman, Treatment of psoriasis in adults; https://www.uptodate.com/contents/treatment-ofpsoriasis-in-adults
- 16. E. Christophers and U. Mrowietz, Psoriasis, in Braun-Falco’s Dermatology (Eds. Burgdorf, Plewig, Wolf, Landthaller), 3rd ed., Springer, Berlin 2009, pp. 506–526.
- 17. E. C. Siegfried, J. C. Jaworski and A. A. Herbert, Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice, Am. J. Clin. Dermatol.14 (2013) 163–178; https://doi.org/10.1007/s40257-013-0020-1
- 18. K. Kragballe and P. C. van de Kerkhof, Consistency of data in six phase III clinical studies of a two compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis, J. Eur. Acad. Dermatol. Venereol20 (2006) 20–39; https://doi.org/10.1111/j.1468-3083.2005.01343.x
- 19. P. Asawanonda and Y. Nateetongrungsak, Methotrexate plus narrowband UVB phototherapy versus narowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study, J. Am. Acad. Dermatol.54 (2006) 1013–1018; https://doi.org/10.1016/j.jaad.2006.01.004
- 20. A. Tanew, A. Guggenbichler, H. Honigsmann, J. M. Geiger and P. Fritsch, Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study, J. Am. Acad. Dermatol.25 (1991) 682–684.
- 21. M. Kaštelan, N. Puizina Ivić, R. Čeović, Z. Jukić, V. Bulat, E. Simonić, L. Prpić Massari, I. Brajac and G. Krnjević Pezić, Guidelines for the diagnosis and treatment of psoriasis, Liječ. Vjesn.135 (2013) 195–200.
- 22. A. Nast, L. Amelunxen, M. Augustin, W-H. Boehncke, C. Dressler, M. Gaskins, P. Harle, B. Hoffstadt, J. Klauss, J. Koza, U. Mrowietz, H-M. Ockenfels, S. Philipp, K. Reich, T. Rosenbach, B. Rzany, M. Schlager, G. Schmid-Ott, M. Sebastian, R. Von Kiedrowski and T. Weberschock, S3 Guideline for the treatment of psoriasis vulgaris, update-short version part 1-systemic treatment, JDDG16 (2018) 645–669; https://doi.org/10.1111/ddg.13516
- 23. A. Nast, P. I. Spuls, G. Van der Kraaij, P. Gisondi, C. Paul, A. D. Ormerod, P. Saiag, C. H. Smith, E. Dauden, E. M. de Jong, E. Feist, R. Jobling, M. Maccarone, U. Mrowietz, K. A. Papp, K. Reich, S. Rosumeck, T. Talme, H. B. Thio, P. van der Kerkhof, R. N. Werner and C. Dressler, European S3-Guideline on the systemic treatment of psoriasis vulgaris-update apremilast and secukinumab-EDF in cooperation with EADV and IPC, J. Eur. Acad. Dermatol. Venereol.31 (2017) 1951–1963; https://doi.org/10.1111/jdv.14454
- 24. S. K. Mahil, F. Capon and J. N. Barker, Update on psoriasis immunopathogenesis and targeted immunotheapy, Semin Immunpathol.38 (2016) 11–27 https://doi.org/10.1007/s00281-015-0539-8
- 25. P. Rich, M. Gooderham, H. Bachelez, J. Goncalves, R. M. Day, R. Chen and J. Crowley. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult to treat nail and scalp psoriasis: result of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM2), J. Am. Acad. Dermatol.74 (2016) 134–142; https://doi.org/10.1016/j.jaad.2015.09.001
- 26. M. AbuHilal, S. Walsh and N. Shear, Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: A retrospective study, J. Cutan. Med. Surg.20 (2016) 313–316; https://doi.org/10.1177/1203475416631328
- 27. L. Hsu, B. T. Snodgrass and A. W. Armstrong. Antidrug antibodies in psoriasis: a systematic review, Br. J. Dermatol.170 (2014) 261–273; https://doi.org/10.1111/bjd.12654
- 28. K. Papp, H. Bachelez, A Constanzo, P. Foley, M. Gooderham, P. Kaur, J. Narbutt, S. Philipp, L. Spelman, J. Weglowska, N. Zhang and B. Strober, Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter phase III study, J. Am. Acad. Dermatol.76 (2017) 1093–1102; https://doi.org/10.1016/j.jaad.2016.12.014
- 29. T. Bito, R. Nishikawa, M. Hatakeyama, A. Kikusawa, H. Kanki, H. Nagai, Y. Sarayama, T. Ikeda, H. Yoshizaki, H. Seto, A. Adachi, T. Horikawa, M. Oka and C. Nishigiri, Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis, Br. J. Dermatol.170 (2014) 922–929; https://doi.org/10.1111/bjd.12791.
- 30. K. K. Jorgensen, I. C. Olsen, G. L. Goll, M. Lorentzen, N. Bolstad, E. A. Haavardsholm, K. E. A. Lundin, C. Mork, J. Jahnsen and T. K. Kvien, Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non inferiority trial, Lancet389 (2017) 2304–2316 https://doi.org/10.1016/S0140-6736(17)30068-5
- 31. K. Reich, A. D. Burden, J. N. Eaton and N. S. Hawkins, Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials, Br. J. Dermatol.166 (2012) 179–188; https://doi.org/10.1111/j.1365-2133.2011.10583.x
- 32. C. Ryan, C. L. Leonardi, J. G. Krueger A. B. Kimball, B. E. Strober, K. B. Gordon, R. G. Langley, J. A. de Lemos, Y. Daud, D. Blankenship, S. Kazi, D. H. Kaplan, V. E. Friedewald and A. Menter, Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials, JAMA306 (2011) 864–871; https://doi.org/10.1001/jama.2011.1211
- 33. K. A. Papp, C. E. Griffiths, K. Gordon, M. Lebwohl, P. O. Szapary, Y. Wasfi, D. Chan, M. C. Hsu, V. Ho, P. D. Ghislain, B. Strober, K. Reich and PHOENIX 1 Investigators, PHOENIX 2 Investigators, ACCEPT Investigators, Long-term safety of ustekinumab in patients with moderate to severe psoriasis: final results from 5 years of follow-up, Br. J. Dermatol.168 (2013) 844–854; https://doi.org/10.1111/bjd.12214
- 34. A. Blauvelt, Safety of secukinumab in the treatment of psoriasis, Expert Opin. Drug Saf.15 (2016) 1413–1420; https://doi.org/10.1080/14740338.2016.1221923
- 35. K. B. Gordon, A. Blauvelt, P. Foley, M. Song, Y. Wasfi, B. Randazzo, Y. K. Shen, Y. You and C. E. M. Griffiths, Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies, Br. J. Dermatol.178 (2018) 132–139; https://doi.org/10.1111/bjd.16008
- 36. K. Papp, D. Thaci, K. Reich, A. Blauwelt, E. Riedl, R. G. Langley, J. G. Krueger, A. B. Gottlieb, H. Nakagawa, E. P. Bowman, A. Mehta, Q. Li, Y. Zhou and R. Shames. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial, Br. J. Dermatol.173 (2015) 930–939. https://doi.org/10.1111/bjd.13932
- 37. K. A. Papp, A. Blauvelt, M. Bukhalo, M. Gooderham, J. G. Krueger, J. P. Lacour, A. Menter, S. Philipp, H. Sofen, S. Tyring, B. R. Berner, S. Visvanathan, C. Pamulapati, N. Bennett, M. Flack, P. Scholl and S. J. Padula, Risankizumab versus Ustekinumab for moderate-to-severe plaque psoriasis, N. Eng. J. Med.376 (2017) 1551–1560; https://doi.org/10.1056/NEJMoa1607017
- 38. M. Amin, D. J. No, A. Egeberg and J. J. Wu, Choosing first-line biologic treatment for moderate-to-severe psoriasis: What does the evidence say? Am J. Clin. Dermatol.19 (2018) 1–13; https://doi.org/10.1007/s40257-017-0328-3
- 39. K. Ronholt and L. Iversen, Old and new biological therapies for psoriasis, Int. J. Mol. Sci.18 (2017) E2297; https://doi.org/103390/ijms18112297
- 40. U. Mrowietz, Implementing treatment goals for successful long-term management of psoriasis, J. Eur. Acad. Dermatol. Venereol26 (2012) 12–20; https://doi.org/10.1111/j.1468-3083.2011.04411.x
- 41. A. Osmola-Mankowska, E. Teresiak-Mikolajczak, M. Skrzypczak-Zielinska and Z. Adamski, Genetic polymorphism in psoriasis and its meaning for the treatment efficacy in the future, Postepy Dermatol. Alergol.35 (2018) 331–337; https://doi.org/10.5114/ada.2018.77